Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: Indivior Pharmaceuticals, Inc.

Market Cap 4.67B 4.07B 3.77B 3.53B 6.62B 441B 6.66B 44.73B 17.34B 217B 17.53B 17.15B 753B P/E 2026 *
12.1x
P/E 2027 * 11.1x
Enterprise Value 4.72B 4.12B 3.81B 3.57B 6.7B 446B 6.74B 45.26B 17.54B 219B 17.73B 17.35B 762B EV / Sales 2026 *
3.76x
EV / Sales 2027 * 3.31x
Free-Float
94.92%
Yield 2026 *
-
Yield 2027 * -
1 week+5.27%
1 month+20.78%
3 months+60.36%
6 months+29.91%
Current year+20.90%
1 week 1,160
Extreme 1160
1,264
1 month 975.5
Extreme 975.5
1,264
3 years 554.83
Extreme 554.83
2,020
5 years 335
Extreme 335
2,020
Change 5-day change 1-year change 3-year change Capi.($)
+1.56%+5.27%+49.52%-20.18% 4.67B
-1.21%-3.04%+44.03%+142.51% 980B
-2.48%-5.18%+52.47%+39.36% 550B
-2.14%-4.94%+16.83%+58.18% 382B
-0.19%-3.09%+23.33%+16.78% 316B
-0.09%+0.21%+26.95%+14.04% 272B
+0.13%-1.30%+24.80%+31.76% 268B
-0.85%+2.07%-35.32%-46.32% 199B
-1.19%-4.95%+16.68%+48.70% 182B
-1.35%-1.46%+14.06%+59.46% 154B
Average -1.04%-2.70%+23.34%+34.43% 366.93B
Weighted average by Cap. -1.21%-3.50%+29.68%+63.45%

Financials

2026 *2027 *
Net sales 1.26B 1.1B 1.02B 951M 1.78B 119B 1.79B 12.05B 4.67B 58.42B 4.72B 4.62B 203B 1.29B 1.12B 1.04B 973M 1.83B 121B 1.84B 12.33B 4.78B 59.79B 4.83B 4.73B 208B
Net income 414M 361M 335M 313M 588M 39.11B 591M 3.97B 1.54B 19.25B 1.56B 1.52B 66.84B 455M 397M 367M 344M 645M 42.92B 649M 4.36B 1.69B 21.13B 1.71B 1.67B 73.36B
Net Debt 54.5M 47.52M 44.01M 41.2M 77.27M 5.14B 77.73M 522M 202M 2.53B 205M 200M 8.79B -403M -352M -326M -305M -572M -38.06B -575M -3.86B -1.5B -18.74B -1.51B -1.48B -65.06B
Logo Indivior Pharmaceuticals, Inc.
Indivior Pharmaceuticals, Inc. is a global pharmaceutical company engaged in developing medicines to treat substance-use disorders (SUD). The Company provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. It sells its products in the United States and in other selected areas of the world.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
38.30USD
Average target price
50.71USD
Spread / Average Target
+32.41%

Quarterly revenue - Rate of surprise

-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!